| 24.01. | Albireo Pharma Investor Alert By The : Kahn Swick & Foti, LLC Investigates Adequacy of Pri.. |  |
| 20.01. | Insider Sell: Albireo Pharma | |
| 11.01. | North American Morning Briefing: Stock Futures -2- | |
| 11.01. | Albireo Pharma Investor Alert By The : Kahn Swick & Foti, LLC Investigates Adequacy of Pri.. | |
| 10.01. | North American Morning Briefing: More Hawkish Fed -2- | |
| 09.01. | Top Midday Gainers | |
| 09.01. | Albireo bondit après l'annonce de son rachat par Ipsen |  |
| 09.01. | Ipsen va acquérir Albireo pour un montant qui pourrait approcher 1,2 md de dollars | |
| 09.01. | Sector Update: Health Care Stocks Mixed Pre-Bell Monday | |
| 09.01. | Top Premarket Gainers | |
| 09.01. | Ipsen va acquérir Albireo pour un montant qui pourrait dépasser 1,1 md de dollars | |
| 09.01. | Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatme.. | |
| 09.01. | Albireo Pharma, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosur.. | |
| 09.01. | Albireo Pharma to be Acquired by Ipsen | |
| 09.01. | Il en faut peu pour être heureux | |
| 09.01. | Bolsa de Madrid: No hace falta mucho para ser feliz |  |
| 09.01. | France's Ipsen Moves to Broaden Rare Disease Portfolio Via $952 Million Purchase of Alb.. | |
| 09.01. | En direct des marchés : Orange, Dassault Systèmes, Euroapi, Elis, .. | |
| 09.01. | AstraZeneca boosts heart, kidney business with $1.8 bln CinCor deal | |
| 09.01. | Ipsen va acquérir Albireo pour un montant initial de 952 millions de dollars | |
| 09.01. | Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatme.. | |
| 09.01. | Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Al.. | |
| 2022 | Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Albireo Pharma Submits Applications for Second Bylvay Indication in US, Europe | |
| 2022 | Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA | |
| 2022 | Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and .. | |
| 2022 | Albireo Appoints Paul Streck, M.D., as Chief Medical Officer and Craig Hopkinson, M.D.,.. | |
| 2022 | Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure.. | |
| 2022 | Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., t.. | |
| 2022 | Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson .. | |
| 2022 | Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (.. | |
| 2022 | Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (.. | |
| 2022 | Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &.. | |
| 2022 | Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 &.. | |
| 2022 | Albireo to Participate in Jefferies London Healthcare Conference | |
| 2022 | Albireo Pharma Swings to Q3 Loss, Revenue Rises; Shares Drop | |
| 2022 | ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R.. | |
| 2022 | Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End.. | |
| 2022 | Earnings Flash (ALBO) ALBIREO PHARMA Reports Q3 Revenue $9.8M, vs. Street Est of $9.54M | |
| 2022 | Albireo Reports Q3 2022 Financial Results and Business Update | |
| 2022 | Albireo Pharma, Inc. - Bylvay Data Presented at AASLD The Liver Meeting 2022, Demonstra.. | |
| 2022 | Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Nat.. | |
| 2022 | Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liv.. | |
| 2022 | Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay in Biliary Atresia | |
| 2022 | Albireo Announces 2022 SPARK Grant Winners | |
| 2022 | Albireo Pharma Completes Patient Enrollment in Phase 3 Trial for Biliary Atresia Treatm.. | |
| 2022 | Albireo to Present Late Breaking Bylvay Data at AASLD 2022 | |
| 2022 | Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia | |
| 2022 | Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary At.. | |
| 2022 | Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022 | |
| 2022 | Albireo Pharma, Inc. to Present Late Breaking Bylvay Data at AASLD 2022 | |
| 2022 | Albireo to Report Q3 2022 Financial Results on November 8, 2022 | |
| 2022 | Albireo annuncia i risultati cardine dello studio di Fase 3 di Bylvay® (odevixibat) nel.. |  |
| 2022 | Albireo annonce des données clés positives à l'issue de la phase III sur Bylvay® (odevi.. | |
| 2022 | Albireo informa de datos positivos de primera línea del ensayo de fase 3 sobre Bylvay® .. | |
| 2022 | Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay Treatment at NASP.. | |
| 2022 | Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NAS.. | |
| 2022 | Albireo Pharma, Inc. Presents Data on Greater Efficacy in PFIC with Earlier Bylvay Trea.. | |
| 2022 | Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay in Alagille Syndrome | |
| 2022 | Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference | |
| 2022 | Health Care Up Slightly As Amgen Rallies -- Health Care Roundup | |
| 2022 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | |
| 2022 | Albireo Pharma Says Late-Stage Trial of Bylvay for Alagille Syndrome Meets Primary Endp.. | |
| 2022 | Albireo Pharma, Inc. : Results of Operations and Financial Condition, Other Events, Financ.. | |
| 2022 | Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Ala.. | |
| 2022 | Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Ala.. | |
| 2022 | Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® in Ala.. | |
| 2022 | Albireo to Showcase New Data at AASLD The Liver Meeting® 2022 | |
| 2022 | Albireo to Showcase New Data at AASLD The Liver Meeting® 2022 | |
| 2022 | Albireo Reports Inducement Grant under Nasdaq Listing Rule 5635(4) | |
| 2022 | Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Albireo Pharma Secures $115 Million Funding From Sagard Healthcare Partners for Liver D.. | |
| 2022 | Albireo Pharma, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosur.. | |
| 2022 | Albireo Announces $115 Million Royalty Monetization Agreement with Sagard | |
| 2022 | Albireo to Participate in Guggenheim Nantucket Therapeutics Conference | |
| 2022 | Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Biote.. | |
| 2022 | Albireo Pharma Says Italian Regulator Approves Reimbursed Access to Bylvay to Treat Liv.. | |
| 2022 | L'Agenzia Italiana del Farmaco approva il rimborso di Bylvay® (odevixibat) per i pazien.. | |
| 2022 | Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patient.. | |
| 2022 | Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of.. | |
| 2022 | Albireo to Participate in Upcoming Investor Conferences | |
| 2022 | Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Albireo Pharma : Management Change/Compensation - Form 8-K/A | |
| 2022 | ALBIREO PHARMA, INC. Change in Directors or Principal Officers (form 8-K/A) | |
| 2022 | Albireo Pharma, Inc. : Entry into a Material Definitive Agreement, Termination of a Materi.. | |
| 2022 | ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R.. | |
| 2022 | Albireo Pharma Q2 Loss Widens, Revenue Increases; Shares Sink After Hours | |
| 2022 | Albireo Pharma : Reports Q2 2022 Financial Results and Business Update - Form 8-K | |
| 2022 | Earnings Flash (ALBO) ALBIREO PHARMA Reports Q2 Revenue $8.2M | |
| 2022 | Earnings Flash (ALBO) ALBIREO PHARMA Reports Q2 Revenue $8.2M, vs. Street Est of $9.52M | |
| 2022 | Albireo Reports Q2 2022 Financial Results and Business Update | |
| 2022 | Albireo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months End.. | |
| 2022 | North American Morning Briefing: Stock Futures -2- | |
| 2022 | Albireo Pharma, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure.. | |
| 2022 | Albireo Pharma : Appoints New Members to Board of Directors - Form 8-K | |
| 2022 | Albireo Appoints New Members to Board of Directors | |
| 2022 | Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its.. | |
| 2022 | Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference | |
| 2022 | Albireo to Report Q2 2022 Financial Results on August 15, 2022 | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
